Related Experiment Video

Updated: Jul 14, 2026

Isolation of Human Endometrial Stromal Cells for In Vitro Decidualization
14:55

Isolation of Human Endometrial Stromal Cells for In Vitro Decidualization

Published on: September 1, 2018

Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers

Hideki Sakaguchi1, Jiro Fujimoto, Wen-Shu Sun

  • 1Department of Obstetrics and Gynecology, Gifu University School of Medicine, 1-1 Yanagido, Gifu City 501-1194, Japan. gucci555@nifty.com

The Journal of Steroid Biochemistry and Molecular Biology
|May 29, 2007
PubMed

Insights

Steroid receptor coactivator-3 (SRC-3) mRNA levels indicate uterine endometrial cancer progression. Higher SRC-3 expression correlates with poor prognosis and advanced disease stages.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gynecologic Oncology

Background:

  • Estrogen significantly influences uterine endometrial cancer development, growth, and invasion.
  • Steroid receptor coactivator-3 (SRC-3) is a coactivator for estrogen receptors and is overexpressed in various cancers.
  • The expression pattern and clinical significance of SRC-3 in uterine endometrial cancer remain incompletely understood.

Purpose of the Study:

  • To investigate the expression of SRC-3 mRNA in uterine endometrial cancer.
  • To determine the correlation between SRC-3 mRNA levels and clinicopathological features.
  • To evaluate the prognostic value of SRC-3 mRNA expression in uterine endometrial cancer patients.

Main Methods:

  • Quantitative analysis of SRC-3 mRNA expression in uterine endometrial cancer tissues.
  • Correlation analysis between SRC-3 mRNA levels and clinical stage, myometrial invasion depth, and tumor differentiation.
  • Survival analysis comparing patients with high versus low SRC-3 mRNA expression.

Main Results:

  • SRC-3 mRNA expression was found to correlate with clinical stage, depth of myometrial invasion, and dedifferentiation.
  • Patients with higher SRC-3 mRNA expression exhibited a significantly poorer prognosis (36% 24-month survival).
  • Patients with lower SRC-3 mRNA expression had a much better 24-month survival rate (96%).

Conclusions:

  • SRC-3 mRNA expression is closely associated with the advancement of uterine endometrial cancer.
  • SRC-3 may serve as a valuable prognostic biomarker for uterine endometrial cancer.
  • Targeting SRC-3 could potentially offer therapeutic strategies for improving patient survival.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...